Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors’ Reply

被引：0
|
作者：
Sean D. Sullivan
Kavita Patel
Jesse Green
机构：
[1] University of Washington,
[2] Roche,undefined
来源：
PharmacoEconomics | 2004年 / 22卷
关键词：
Major Public Health Concern; Simulated Population; Incremental Benefit; Fibrosis Progression; Male Cohort;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：478 / 478
相关论文
共 50 条
  • [41] Peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients
    Crespo, M
    Sauleda, S
    Esteban, JI
    Juarez, A
    Buti, M
    Pahissa, A
    Esteban, R
    Guardia, J
    HEPATOLOGY, 2005, 42 (04) : 701A - 702A
  • [42] Peginterferon alfa-2b plus ribavirin for chronic hepatitis - Reply
    Manns, MP
    McHutchison, J
    Koury, K
    Albrecht, JK
    LANCET, 2002, 359 (9302): : 264 - 264
  • [43] Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
    McHutchison, JG
    Poynard, T
    SEMINARS IN LIVER DISEASE, 1999, 19 : 57 - 65
  • [44] A comparison of cost-effectiveness of peginterferon alfa-2a (40 KD) (pegasys) plus ribavirin (copegus) versus interferon alfa-2b Plus ribavirin as first treatment of chronic hepatitis C in the UK
    Lewis, GJ
    Green, J
    Patel, K
    Philips, Z
    VALUE IN HEALTH, 2004, 7 (06) : 763 - 764
  • [45] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C - Reply
    Fried, MW
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 260 - 260
  • [46] Efficacy and tolerability of pegylated interferon alpha-2a plus ribavirin versus pegylated interferon alpha-2b plus ribavirin, in treatment naive chronic hepatitis C patients
    Lee, S. Y.
    Lee, S.
    Ko, K. S.
    Kim, I. H.
    Kim, S. H.
    Kim, S. W.
    Lee, S. O.
    Lee, S. T.
    Kim, D. G.
    Choi, C. S.
    Cho, E. Y.
    Kim, H. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A176 - A176
  • [47] Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C
    Kim, WR
    Poterucha, JJ
    Gross, JB
    HEPATOLOGY, 2000, 31 (03) : 807 - 807
  • [48] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Mosaburo Kainuma
    Norihiro Furusyo
    Eiji Kajiwara
    Kazuhiro Takahashi
    Hideyuki Nomura
    Yuichi Tanabe
    Takeaki Satoh
    Toshihiro Maruyama
    Makoto Nakamuta
    Kazuhiro Kotoh
    Koichi Azuma
    Junya Shimono
    Shinji Shimoda
    Jun Hayashi
    World Journal of Gastroenterology, 2010, 16 (35) : 4400 - 4409
  • [49] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Kainuma, Mosaburo
    Furusyo, Norihiro
    Kajiwara, Eiji
    Takahashi, Kazuhiro
    Nomura, Hideyuki
    Tanabe, Yuichi
    Satoh, Takeaki
    Maruyama, Toshihiro
    Nakamuta, Makoto
    Kotoh, Kazuhiro
    Azuma, Koichi
    Shimono, Junya
    Shimoda, Shinji
    Hayashi, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (35) : 4400 - 4409
  • [50] Interferon-β induction/interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C
    Kim, KI
    Sasase, N
    Taniguchi, M
    Mita, K
    Kinoshita, K
    Togitani, T
    Shikata, M
    Kimura, N
    Izawa, S
    Ohtani, A
    Nakao, K
    Muramoto, Y
    Kim, SR
    Nabeshima, S
    Ishii, F
    Tanaka, K
    Hayashi, Y
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 2005, 25 (02) : 71 - 76
12345